EIIIB

Product List

Creative Biolabs supplies extensive anti-EIIIB CART products and services to support CART development for global customers. Our technical team is very pleased to receive any inquiry about CART development, please do not hesitate to contact us.

Background

EIIIB is a fibronectin spliced variant that is strongly expressed in tumor stroma and neovasculature, but not in many normal tissues. Several studies showed that increased extracellular matrix (ECM) deposition is one of the important features of cancer, fibrosis, and inflammatory diseases. EIIIB serves as an important ECM marker, making it an attractive target for imaging and therapeutic approaches. EIIIB-CAR-T cells have been developed to treat tumors and regulate TME.

Fig.1 Schematic representation of EIIIB Expression at the tumors and metastatic sites by H&E staining and IHC using EIIIB antibody clone NJB2.¹

Associated Diseases

Pancreatic ductal adenocarcinoma

Fibrosis

Inflammatory disorders

Others

Anti-EIIIB CAR-T Services

Anti-EIIIB CAR-T In Vitro Assays

Anti-EIIIB CAR-T Expression Test

CAR expression detection by flow cytometry using recombinant antigen protein is an effective means of CAR test, which is convenient and easy to operate for CART development. Creative Biolabs has developed various kinds of CAR detection reagents to support CAR expression tests, including antigen-specific antigen protein with sensitive fluorescence and CAR linker detection reagents. Meanwhile, we supply several appropriate and robust methods for CAR expression detection, such as qPCR, WB, and Flow cytometry.

Fig.2 CAR expression test of Anti-EIIIB fibronectin-targeted CAR T cells by flow cytometry. Anti-EIIIB CART cells were incubated with recombinant EIIIB-GST and detected by rabbit anti-GST and anti-rabbit A647 secondary antibody.²

Anti-EIIIB CAR-T In Vitro Cytotoxicity Assay

EIIIB-specific CAR T cells (B2 CAR) exhibited increased cytotoxicity against aortic endothelial cells (FN+/+) at the specific E:T ratio. At Creative Biolabs, we offer optimized cytotoxicity assay services to validate the specificity and cytotoxicity of CART cells to speed up global customers’ projects.

Fig.3 In vitro cytotoxicity assay of anti-EIIIB CAR-T (B2 CAR) against aortic endothelial cells (AEC) expressing the EIIIB fibronectin domain (FN+/+) at the indicated E:T ratio.²

In addition, we are dedicated to providing a wide range of in vitro test for CART development, including but not limited to:

Anti-EIIIB CAR-T Cytokine Release Test

Anti-EIIIB CAR-T Cell Proliferation Assay

Anti-EIIIB CAR-T Cell Phenotype Analysis

Anti-EIIIB CAR-T In Vivo Assays

Efficacy Test of Anti-EIIIB CAR-T

To test the degree of efficacy of CAR T cells against tumors, we have established an extensive range of animal models to conduct efficacy validation. According to the characteristics of different targets, we designed optimized animal experiments to further detect the in vivo efficacy of CART cells.

Fig.4 In vivo efficacy test of EIIIB CAR-T cells against B16 bearing-tumor. (A) Schematic diagram of in vivo mouse model for EIIIB CAR-T evaluation. (B) The tumor area measurement of in vivo model treated with CART cells.²

Toxicity Evaluation Anti-EIIIB CAR-T

To more closely analyze the mechanisms of efficacy and toxicity of CART cells, Creative Biolabs specializes in offering a variety of toxicological evaluation services to aid in CART development, including but not limited to off-target toxicity analysis, tumorigenicity studies, etc.

Immune Infiltration Test of Anti-EIIIB CAR-T

Fig.5 Necrotic analysis of tumors samples from mouse model treated with EIIIB CAR T cells to test immune infiltration.²

Immunogenicity Analysis of Anti-EIIIB CAR-T

Fig.6 Anti-EIIIB clone B2 response of serum from B16-bearing WT mice treated with EIIIB CAR-T to test immunogenicity.²

References

1. Jailkhani, Noor, et al. "Noninvasive imaging of tumor progression, metastasis, and fibrosis using a nanobody targeting the extracellular matrix." Proceedings of the National Academy of Sciences 116.28 (2019): 14181-14190.
2. Xie, Yushu Joy, et al. "Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice." Proceedings of the National Academy of Sciences 116.16 (2019): 7624-7631.